259 related articles for article (PubMed ID: 14722073)
61. Attenuation of estrogen receptor alpha-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor.
Aiyar SE; Sun JL; Blair AL; Moskaluk CA; Lu YZ; Ye QN; Yamaguchi Y; Mukherjee A; Ren DM; Handa H; Li R
Genes Dev; 2004 Sep; 18(17):2134-46. PubMed ID: 15342491
[TBL] [Abstract][Full Text] [Related]
62. Molecular determinants for the tissue specificity of SERMs.
Shang Y; Brown M
Science; 2002 Mar; 295(5564):2465-8. PubMed ID: 11923541
[TBL] [Abstract][Full Text] [Related]
63. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression.
Li J; Lin Q; Wang W; Wade P; Wong J
Genes Dev; 2002 Mar; 16(6):687-92. PubMed ID: 11914274
[TBL] [Abstract][Full Text] [Related]
64. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
65. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Shah YM; Rowan BG
Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
[TBL] [Abstract][Full Text] [Related]
66. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Li Y; Birnbaumer L; Teng CT
Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
[TBL] [Abstract][Full Text] [Related]
67. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Kim K; Thu N; Saville B; Safe S
Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
[TBL] [Abstract][Full Text] [Related]
68. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo.
Atsumi A; Tomita A; Kiyoi H; Naoe T
Biochem Biophys Res Commun; 2006 Jul; 345(4):1471-80. PubMed ID: 16730330
[TBL] [Abstract][Full Text] [Related]
69. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
70. Differential impact of flanking sequences on estradiol- vs 4-hydroxytamoxifen-liganded estrogen receptor binding to estrogen responsive element DNA.
Anolik JH; Klinge CM; Bambara RA; Hilf R
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):713-30. PubMed ID: 8274405
[TBL] [Abstract][Full Text] [Related]
71. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
72. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Obrero M; Yu DV; Shapiro DJ
J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
[TBL] [Abstract][Full Text] [Related]
73. Phosphorylation of Estrogen Receptor α at serine 118 directs recruitment of promoter complexes and gene-specific transcription.
Duplessis TT; Williams CC; Hill SM; Rowan BG
Endocrinology; 2011 Jun; 152(6):2517-26. PubMed ID: 21505052
[TBL] [Abstract][Full Text] [Related]
74. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists.
Huang HJ; Norris JD; McDonnell DP
Mol Endocrinol; 2002 Aug; 16(8):1778-92. PubMed ID: 12145334
[TBL] [Abstract][Full Text] [Related]
75. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
76. Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites.
Ivanova MM; Luken KH; Zimmer AS; Lenzo FL; Smith RJ; Arteel MW; Kollenberg TJ; Mattingly KA; Klinge CM
FASEB J; 2011 Apr; 25(4):1402-16. PubMed ID: 21233487
[TBL] [Abstract][Full Text] [Related]
77. Involvement of HP1alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells.
Oliva J; El Messaoudi S; Pellestor F; Fuentes M; Georget V; Balaguer P; Cavaillès V; Vignon F; Badia E
FEBS Lett; 2005 Aug; 579(20):4278-86. PubMed ID: 16051232
[TBL] [Abstract][Full Text] [Related]
78. The structure of the core NuRD repression complex provides insights into its interaction with chromatin.
Millard CJ; Varma N; Saleh A; Morris K; Watson PJ; Bottrill AR; Fairall L; Smith CJ; Schwabe JW
Elife; 2016 Apr; 5():e13941. PubMed ID: 27098840
[TBL] [Abstract][Full Text] [Related]
79. Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5.
Gao H; Lukin K; Ramírez J; Fields S; Lopez D; Hagman J
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11258-63. PubMed ID: 19549820
[TBL] [Abstract][Full Text] [Related]
80. Coactivator-mediated estrogen response in human squamous cell carcinoma lines.
Ku TK; Crowe DL
J Endocrinol; 2007 Apr; 193(1):147-55. PubMed ID: 17400812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
